Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYS6002 vs Chemotherapy in Advanced Urothelial Carcinoma
NCT07526792Phase 3Not yet recruiting
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- Jun 2026
- Primary completion
- Jun 2029
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
A Phase 3 trial of CRB-701 in urothelial carcinoma (UC), sponsored by CSPC Megalith Biopharmaceutical Co., Ltd.. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
CRB-701
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT07526792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07526792.